Company & Sponsor Intelligence

Newron Pharmaceuticals SPA

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials5

Recruiting0

Completed5

Countries3

Therapeutic footprint

pain_neuropathyparkinsonsschizophrenia

Indexed studies

NCT00605683MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
parkinsons · United StatesPHASE3

NCT02624167A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
schizophrenia · United StatesPHASE2

NCT01026428A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
parkinsons · ItalyPHASE1, PHASE2

NCT00627640Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
parkinsons · United StatesPHASE3

NCT00736151Phase II Dose Titration Study in Patients With Neuropathic Pain
pain_neuropathy · AustriaPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →